ArticleFrontiers in cellular and infection microbiology2026
Gut microbiota and serum metabolic profiles in patients with sepsis-induced cardiomyopathy and their association with the disease.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pathogenesis of sepsis-induced cardiomyopathy (SIC) remains unclear, and the lack of effective treatment options results in high mortality rates. There may be interactions between gut microbiota dysbiosis, serum metabolic changes, and SIC; however, research in this area is limited. This study aims to provide a theoretical basis for targeted interventions to improve the gut microbiome, thereby enhancing cardiac function and prognosis in patients with SIC. Methods: This prospective cohort study enrolled 48 septic patients admitted to the intensive care unit (ICU) of a tertiary general hospital in Ningxia, China, between March 2024 and March 2025. Patients were stratified into SIC (n=28) and SEPSIS (n=20) groups. Age- and sex-matched healthy controls (HC, n=10) were also recruited. Fecal samples from all three groups were analyzed via 16S rRNA gene amplicon sequencing, and serum samples from the SIC and SEPSIS groups were analyzed via LC-MS-based untargeted metabolomics. Spearman's correlations linked microbial and metabolic alterations to echocardiographic parameters and myocardial injury markers. Results: Compared with the SEPSIS and HC groups, the SIC group presented significant differences in both the α and β diversity of the gut microbiota (all P<0.05). Compared with that in the SEPSIS group, the Conclusion: Gut microbiota dysbiosis differs between patients with Sepsis-induced cardiomyopathy and healthy individuals or patients with sepsis. Additionally, the serum metabolic profile changes in SIC patients differ from those in patients with sepsis, and these characteristic changes are significantly associated with clinical indicators related to the diagnosis of SIC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.